» Authors » Jean-Philippe Zurcher

Jean-Philippe Zurcher

Explore the profile of Jean-Philippe Zurcher including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 31
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, et al.
Cancers (Basel) . 2023 Jan; 15(1). PMID: 36612312
The cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib is administered orally and cyclically, causing medication adherence challenges. We evaluated components of adherence to palbociclib, its relationship with pharmacokinetics (PK), and drug-induced...
2.
Courlet P, Cardoso E, Bandiera C, Stravodimou A, Zurcher J, Chtioui H, et al.
Pharmaceutics . 2022 Jul; 14(7). PMID: 35890213
Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic-pharmacodynamic (PK/PD) relationships for toxicity...
3.
Dris N, Meyer M, Flores Torres C, Curtit E, Zurcher J, Stravodimou A, et al.
Rev Med Suisse . 2022 May; 18(782):997-1001. PMID: 35583279
In last years, the therapeutic arsenal against breast cancer increased considerably with the arrival of signaling pathway inhibitors, immunotherapy, PARP inhibitors, tyrosine kinase inhibitors and antibody-drug conjugates. Consequently, the range...
4.
Horisberger A, La Rosa S, Zurcher J, Zimmermann S, Spertini F, Coukos G, et al.
J Immunother Cancer . 2018 Dec; 6(1):156. PMID: 30587227
Background: The prevalence of esophageal stenosis caused by immune checkpoint inhibitors in the context of induced immune mucositis and esophagitis is extremely rare. Case Presentation: We report the case of...
5.
Zurcher J, Stravodimou A, Zaman K
Rev Med Suisse . 2017 Jul; 12(531):1580-1583. PMID: 28678454
Invasive breast cancer is the most common malignancy in women in industrialized countries. Three-quarters of breast cancers express estrogen and/or progesterone receptors and are considered endocrine-sensitive. Endocrine therapy reduces the...